BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 25125888)

  • 1. Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia.
    Griwan MS; Karthikeyan YR; Kumar M; Singh BJ; Singh SK
    Urol Ann; 2014 Jul; 6(3):181-6. PubMed ID: 25125888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia.
    Masumori N
    Ther Clin Risk Manag; 2011; 7():227-38. PubMed ID: 21753885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial.
    Gotoh M; Kamihira O; Kinukawa T; Ono Y; Ohshima S; Origasa H;
    BJU Int; 2005 Sep; 96(4):581-6. PubMed ID: 16104914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.
    Garimella PS; Fink HA; Macdonald R; Wilt TJ
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007360. PubMed ID: 19821408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.
    Hwang EC; Gandhi S; Jung JH; Imamura M; Kim MH; Pang R; Dahm P
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD007360. PubMed ID: 30306544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study.
    Shirakawa T; Haraguchi T; Shigemura K; Morishita S; Minayoshi K; Miyazaki J; Yamada Y; Miyake H; Tanaka K; Fujisawa M
    Int J Urol; 2013 Sep; 20(9):903-10. PubMed ID: 23252453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Naftopidil 75 mg with Tamsulosin Hydrochloride 0.2 mg in the Treatment of Lower Urinary Tract Symptoms with Benign Prostatic Hyperplasia.
    Shigemura K; Yamamichi F; Matsumoto M; Tanaka K; Yamashita M; Arakawa S; Fujisawa M
    Low Urin Tract Symptoms; 2012 Sep; 4(3):136-9. PubMed ID: 26676620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ejaculatory disorders caused by alpha-1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study.
    Masumori N; Tsukamoto T; Iwasawa A; Furuya R; Sonoda T; Mori M;
    Urol Int; 2009; 83(1):49-54. PubMed ID: 19641359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial.
    Tsumura H; Satoh T; Ishiyama H; Tabata K; Kotani S; Minamida S; Kimura M; Fujita T; Matsumoto K; Kitano M; Hayakawa K; Baba S
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e385-92. PubMed ID: 21664068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of naftopidil in the management of benign prostatic hyperplasia.
    Hara N; Mizusawa T; Obara K; Takahashi K
    Ther Adv Urol; 2013 Apr; 5(2):111-9. PubMed ID: 23554846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men.
    Kawabe K; Yoshida M; Homma Y;
    BJU Int; 2006 Nov; 98(5):1019-24. PubMed ID: 16945121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized Crossover Comparison of the Short-Term Efficacy and Safety of Single Half-Dose Silodosin and Tamsulosin Hydrochoride in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
    Takeshita H; Moriyama S; Arai Y; Washino S; Saito K; Chiba K; Horiuchi S; Noro A
    Low Urin Tract Symptoms; 2016 Jan; 8(1):38-43. PubMed ID: 26789541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Singh DV; Mete UK; Mandal AK; Singh SK
    J Sex Med; 2014 Jan; 11(1):187-96. PubMed ID: 24165272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia.
    Manjunatha R; Pundarikaksha HP; Madhusudhana HR; Amarkumar J; Hanumantharaju BK
    Indian J Pharmacol; 2016; 48(2):134-40. PubMed ID: 27127315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the efficacy of naftopidil and tamsulosin hydrochloride in medical treatment of benign prostatic enlargement.
    Perumal C; Chowdhury PS; Ananthakrishnan N; Nayak P; Gurumurthy S
    Urol Ann; 2015; 7(1):74-8. PubMed ID: 25657550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naftopidil for the treatment of benign prostate hyperplasia: a systematic review.
    Castiglione F; Benigni F; Briganti A; Salonia A; Villa L; Nini A; Di Trapani E; Capitanio U; Hedlund P; Montorsi F
    Curr Med Res Opin; 2014 Apr; 30(4):719-32. PubMed ID: 24188134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-Marketing Surveillance of Silodosin in Patients with Benign Prostatic Hyperplasia and Poor Response to Existing Alpha-1 Blockers: The SPLASH Study.
    Takahashi H; Kubono S; Taneyama T; Kuramoto K; Mizutani H; Tanaka N; Yoshida M
    Drugs R D; 2019 Mar; 19(1):47-55. PubMed ID: 30607819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of silodosin in comparison to tamsulosin in benign prostatic hyperplasia: a randomized controlled trial.
    Pande S; Hazra A; Kundu AK
    Indian J Pharmacol; 2014; 46(6):601-7. PubMed ID: 25538330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes and complications of naftopidil versus tamsulosin for elderly men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: A systematic review and meta-analysis.
    Chai Y; Zhou Z; Cui Y; Che X; Zhang Y
    Andrologia; 2021 Oct; 53(9):e14166. PubMed ID: 34189764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.